SEC Comment Letter 0000000000-24-001240 to Applied Therapeutics, Inc. (APLT) (CIK 0001697532)
Applied Therapeutics, Inc. (APLT) (CIK 0001697532)
Date: Jan. 31, 2024 · CIK: 0001697532 · Accession: 0000000000-24-001240
AI Filing Summary & Sentiment
File numbers found in text: 001-38898
Letter
United States securities and exchange commission logo January 31, 2024 Shoshana Shendelman President and Chief Executive Officer Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 Re:Applied Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 23, 2023 File number 001-38898 Dear Shoshana Shendelman: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
January 31, 2024
Shoshana Shendelman
President and Chief Executive Officer
Applied Therapeutics Inc.
545 Fifth Avenue, Suite 1400
New York, NY 10017
Re:Applied Therapeutics Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 23, 2023
File number 001-38898
Dear Shoshana Shendelman:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences